Clinical and mutational profile of AT-rich interaction domain 1A-mutated cancers.
Rosa FalconeMarco FilettiPasquale LombardiValeria AltamuraFrancesco Paroni SterbiniGiovanni ScambiaGennaro DanielePublished in: Exploration of targeted anti-tumor therapy (2023)
cancers, in particular the subgroup of gynecologic cancers. The high frequency of concurrent mutations in the phosphoinositide 3-kinase (PI3K) pathway among endometrioid endometrial cancers may support the proposal of a new treatment strategy based on the combination of ataxia telangiectasia and Rad3-related (ATR) inhibitor and PIK3CA inhibitor.